|Articles|December 1, 2012
- Pharmaceutical Executive-12-01-2012
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - December 2012
The Puzzle Master
Advertisement
Articles in this issue
almost 13 years ago
Obamacare, Innovation and Pricingalmost 13 years ago
Germany's Price Reform Revolutionalmost 13 years ago
Transforming Drug Development: A Lilly–Covance Case Studyalmost 13 years ago
The Puzzle Master: EMA's Guido Rasialmost 13 years ago
Top Medical Innovations for 2013Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
2
Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences
3
GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate
4
ACS Calls Obesity a Condition That Must Be Treated with Medication and Surgery
5
